Latest Hemoglobinopathy Stories
Development Decision Leverages Recent Data with New ZFN-mediated Genome Editing Approach for Both Sickle Cell Disease and Beta-Thalassemia Programs RICHMOND, Calif., May 13, 2015 /PRNewswire/
RICHMOND, Calif., Feb. 4, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc.
RICHMOND, Calif., Feb. 4, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
RICHMOND, Calif., Jan. 9, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
--Partnership to Focus on Developing Novel Therapies for Sickle Cell Disease and Beta-Thalassemia-- CAMBRIDGE, Mass. and RICHMOND, Calif., Jan.
RICHMOND, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that research led by Donald B.
Scientists have discovered why people with a specific type of hemoglobin -- the oxygen-carrying molecule that gives red blood cells their color -- are less prone to severe malaria. In a series of experiments, the researchers determined how hemoglobin type C impairs the ability of malaria parasites to cause disease symptoms.
- A hairdresser.